Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Authors
Keywords
Breast cancer, Discordance, Immunotherapy, Metastasis, PD-L1
Journal
CANCER TREATMENT REVIEWS
Volume 99, Issue -, Pages 102257
Publisher
Elsevier BV
Online
2021-07-01
DOI
10.1016/j.ctrv.2021.102257
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
- (2021) Leisha A Emens et al. JNCI-Journal of the National Cancer Institute
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
- (2021) Hope S Rugo et al. JNCI-Journal of the National Cancer Institute
- Top 10 Challenges in Cancer Immunotherapy
- (2020) Priti S. Hegde et al. IMMUNITY
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- Programmed Death Ligand‐1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
- (2020) Ioannis Zerdes et al. Molecular Oncology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
- (2020) Emily S. Reisenbichler et al. MODERN PATHOLOGY
- Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer
- (2020) William Jacot et al. CLINICAL CHEMISTRY
- Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
- (2020) Raza Syed Hoda et al. MODERN PATHOLOGY
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- How current assay approval policies are leading to unintended imprecision medicine
- (2020) Roberto Salgado et al. LANCET ONCOLOGY
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis
- (2020) Yutian Zou et al. EBioMedicine
- Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data
- (2019) Alexios Matikas et al. CLINICAL CANCER RESEARCH
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
- (2019) Sandra Martinez-Morilla et al. LABORATORY INVESTIGATION
- Primary tumor resection for initially staged IV breast cancer
- (2019) Timuçin Erol et al. MEDICINE
- Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
- (2019) Chenxi Yuan et al. Scientific Reports
- Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
- (2018) Ming Li et al. BMC CANCER
- Immune gene expression and response to chemotherapy in advanced breast cancer
- (2018) Theodoros Foukakis et al. BRITISH JOURNAL OF CANCER
- Clinicopathological correlation of PD-L1 expression in primary and metastatic breast Cancer and infiltrating immune cells
- (2018) Ossama Tawfik et al. HUMAN PATHOLOGY
- PD-L1 in breast cancer: comparative analysis of 3 different antibodies
- (2018) Tejashree Karnik et al. HUMAN PATHOLOGY
- Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- (2018) Willemijne A M E Schrijver et al. JNCI-Journal of the National Cancer Institute
- Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- (2018) Willemijne A M E Schrijver et al. JNCI-Journal of the National Cancer Institute
- Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types
- (2018) L Paré et al. ANNALS OF ONCOLOGY
- Immunological differences between primary and metastatic breast cancer
- (2018) B Szekely et al. ANNALS OF ONCOLOGY
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases
- (2018) Quirine F. Manson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
- (2017) Rin Ogiya et al. Oncotarget
- Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
- (2016) Rin Ogiya et al. CANCER SCIENCE
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2015) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
- (2014) Claudette Falato et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer during follow-up and progression – A population based cohort on new cancers and changed biology
- (2014) E. Karlsson et al. EUROPEAN JOURNAL OF CANCER
- When to order a biopsy to characterise a metastatic relapse in breast cancer
- (2012) T. Foukakis et al. ANNALS OF ONCOLOGY
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started